Last revised by Francesco Sciacca on 2 Aug 2021

Samarium-153 (Sm-153) is a radioisotope used in metabolic radiotherapy for the treatment of pain from bone metastases. It is produced in nuclear reactors, by neutron irradiation of samarium-152 (Sm-152 Sm2O3).

Samarium-153 decays by emitting both beta minus particles and gamma photons with a characteristic gamma peak of 103.2 KeV; it has a physical half-life time of 1.93 days. The carrier molecule used is the ethylene diamine tetramethylene phosphonate acid (EDTMP), a chelator osteotropic tetraphosphonate. The radiopharmaceutical Sm-153 EDTMP (dose: 37 MBq/Kg) shows a biodistribution similar to that of technetium-99m methylene diphosphonate (Tc-99m MDP). The gamma (photons) component also allows the use of the radiotracer for nuclear medical imaging (follow-up).

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.